Supernus Pharmaceuticals, Inc. (LON:0LB2)
44.40
+0.58 (1.32%)
At close: Sep 17, 2025
Supernus Pharmaceuticals Revenue
Supernus Pharmaceuticals had revenue of $165.45M USD in the quarter ending June 30, 2025, a decrease of -1.71%. This brings the company's revenue in the last twelve months to $665.13M, up 5.55% year-over-year. In the year 2024, Supernus Pharmaceuticals had annual revenue of $661.82M with 8.94% growth.
Revenue (ttm)
$665.13M
Revenue Growth
+5.55%
P/S Ratio
3.79
Revenue / Employee
$986.83K
Employees
674
Market Cap
1.84B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 661.82M | 54.30M | 8.94% |
Dec 31, 2023 | 607.52M | -59.72M | -8.95% |
Dec 31, 2022 | 667.24M | 87.46M | 15.09% |
Dec 31, 2021 | 579.78M | 59.38M | 11.41% |
Dec 31, 2020 | 520.40M | 127.64M | 32.50% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 41.24B |
GSK plc | 31.63B |
Haleon | 11.02B |
Smith & Nephew | 4.33B |
ConvaTec Group | 1.72B |
Hikma Pharmaceuticals | 2.35B |
HUTCHMED (China) | 439.54M |
Genus | 672.80M |
Supernus Pharmaceuticals News
- 21 days ago - Supernus Pharmaceuticals to Participate in September Investor Conferences - GlobeNewsWire
- 4 weeks ago - Insider Decision: Frederick Hudson Offloads $315K Worth Of Supernus Pharmaceuticals Stock - Benzinga
- 5 weeks ago - Supernus Pharmaceuticals Stock Scores RS Rating Upgrade - Investor's Business Daily
- 6 weeks ago - Supernus Pharmaceuticals, Inc. (SUPN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Supernus Pharmaceuticals GAAP EPS of $0.40 beats by $0.46, revenue of $165.5M beats by $11.42M - Seeking Alpha
- 6 weeks ago - Supernus Announces Second Quarter 2025 Financial Results - GlobeNewsWire
- 6 weeks ago - Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics - GlobeNewsWire
- 7 weeks ago - Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer - GlobeNewsWire